- Amenamevir
-
- $55.00 / 1mg
-
2025-04-28
- CAS:841301-32-4
- Min. Order:
- Purity: 99.86%
- Supply Ability: 10g
- ASP 2151
-
- $1.00 / 1kg
-
2025-04-27
- CAS:841301-32-4
- Min. Order: 1kg
- Purity: 99
- Supply Ability: kg
- Amenamevir
-
- $1.00 / 1KG
-
2021-04-16
- CAS:841301-32-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 5000KG
|
| | ASP 2151 Basic information |
| Product Name: | ASP 2151 | | Synonyms: | ASP 2151;AMenaMevir;N-(2,6-Dimethylphenyl)tetrahydro-N-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-2H-thiopyran-4-carboxamide 1,1-dioxide;ASP 2151 (Amenamevir);CS-2753;ASP2151;ASP 2151;ASP-2151;N-(2,6-Dimethylphenyl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl] amino}-2-oxoethyl)-1,1-dioxothiane-4-carboxamide;N-(2-((4-(1,2,4-Oxadiazol-3-yl)phenyl)amino)-2-oxoethyl)-N-(2,6-dimethylphenyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | | CAS: | 841301-32-4 | | MF: | C24H26N4O5S | | MW: | 482.55 | | EINECS: | | | Product Categories: | | | Mol File: | 841301-32-4.mol |  |
| | ASP 2151 Chemical Properties |
| density | 1.360±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF:PBS (pH 7.2) (1:20):0.04(Max Conc. mg/mL);0.08(Max Conc. mM)
DMF:2.0(Max Conc. mg/mL);4.14(Max Conc. mM) | | form | A solid | | pka | 12.60±0.70(Predicted) | | color | White to off-white |
| | ASP 2151 Usage And Synthesis |
| Description | Amenamevir is an antiviral inhibitor of herpes simplex virus 1 (HSV-1) helicase-primase complex activity. It inhibits recombinant HSV-1 helicase with an IC50 value of 0.078 μM and recombinant HSV-1 primase when used at concentrations greater than or equal to 0.03 μM. Amenamevir inhibits replication of varicella-zoster virus (VZV), HSV-1, and HSV-2 in human embryonic fibroblast (HEF) cells (EC50s = 0.047, 0.036, and 0.028 μM, respectively) and is not cytotoxic to HEF cells with a 50% cytotoxic concentration (CC50) of greater than 30 μM. Amenamevir also inhibits replication of clinical VZV isolates in HEF cells (EC50s = 0.038-0.10 μM). In vivo, it increases survival of cutaneously HSV-1-infected mice in a zosteriform-spread model of progressive HSV-1 infection (ED50 = 1.9 mg/kg twice per day). | | Uses | Amenamevir is a helicase-primase inhibitor which has potent antiviral activity against HSVs with an EC50 of 14 ng/mL. | | in vivo | Amenamevir (ASP2151) administration accelerates the reduction in virus titer in a dose-dependent manner in the range of 3 to 30 mg/kg/day. Amenamevir treatment decreases both lesion scores and HSV-1 titers in a dose-dependent manner, irrespective of the dosing interval. Based on the correlation curves, the PK parameters at which HSV-1 growth is completely suppressed by oral administration of Amenamevir are estimated to be 10,000 ng/mL or higher for the maximum concentration of drug in serum (Cmax), 60 μg ? h/ml or higher for concentration-time curve over 24 h (AUC24h), and 21 to 24 h for T>100 . The mean concentration of Amenamevir in plasma at 5 days postinfection increases in a dose-dependent manner, with doses of 3 mg Amenamevir/g or higher significantly reducing the intradermal HSV-1 titer[1]. | | IC 50 | HSV-1: 7.7-20 ng/mL (IC50); HSV-2: 15-58 ng/mL (IC50) |
| | ASP 2151 Preparation Products And Raw materials |
|